Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2015-01-12 Capital/Financing Update
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 12, 2015, by TapImmune Inc. It details the entry into a material definitive agreement, specifically a Securities Purchase Agreement for a registered public offering of units consisting of common stock and multiple series of warrants. The document includes descriptions of the securities, placement agent agreements, and related exhibits. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The content focuses on a capital raising transaction and related agreements. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (9744 characters) supports it being a full filing rather than a brief announcement. Confidence is high due to the clear description of a financing transaction and the use of Form 8-K Item 1.01 (Entry into a Material Definitive Agreement) which typically covers capital raising events.
2015-01-12 English
SCHEDULE 13G
Major Shareholding Notification
2015-01-12 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering of units consisting of common stock and warrants. It details the terms of the offering, pricing, use of proceeds, placement agents, and risk factors. The document is a registration and offering prospectus supplement, which is a capital raising document. It is not a financial report, earnings release, management discussion, or any other type of report. It clearly relates to a financing activity and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed offering terms, consistent with a capital raising filing rather than a brief announcement or regulatory filing.
2015-01-12 English
Interim / Quarterly Report 2014
Interim / Quarterly Report 9M 2014
2014-11-19 English
Regulatory Filings 2014
Regulatory Filings Classification · 100% confidence The document is a Form 12B-25, which is a Notification of Late Filing for a Form 10-Q quarterly report. It states that the quarterly report for the period ended September 30, 2014, has not been completed due to administrative delays and will be filed soon. The document does not contain the actual financial statements or substantive financial data of the 10-Q report itself, but rather is an announcement regarding the delay in filing that report. The document length is short (2010 characters), consistent with a notification rather than a full report. According to the rules, such a notification should be classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the filing status, not the report itself.
2014-11-14 English
Board/Management Information 2014
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed by TapImmune Inc. It specifically reports a change in the company's independent registered public accounting firm, detailing the dismissal of the previous auditor and appointment of a new auditor. The content focuses on auditor changes and related disclosures, which aligns with announcements about changes in company management or board-related matters. It is not a full audit report, annual report, or financial statement, but rather a regulatory filing reporting a management-related event. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length is 4712 characters, which is consistent with a detailed 8-K filing but not a full financial report.
2014-11-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.